MHRAsafety guidance72% confidence
Clinical trials for medicines: ending a clinical trial
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Gilead.
Regulatory Analysis
Guidance on the process for ending a clinical trial.
Supporting Context
- Therapeutic area
- Infectious Disease · HIV
- Sub-indication
- General
Related signal: Islatravir and Lenacapavir Show Sustained Virologic Suppression in Phase 3 HIV Trials